GeoVax Advances GEO-MVA Vaccine Program with Clinical Supplies Release

GeoVax Labs has completed release testing for its GEO-MVA vaccine program, which aims to protect against mpox and smallpox. The clinical product has passed testing and is scheduled for final release in early April, paving the way for the planned pivotal Phase 3 clinical study. The company is advancing toward a pivotal inflection point, moving toward potential regulatory approval and commercialization.